InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Brian Luque, Director of Investor Relations, is scheduled to present at the 2013 Aegis Healthcare Conference to be held September 25-28, 2013 at The Encore at Wynn Las Vegas. The Company’s presentation will be on Thursday, September 26th at 2:00 p.m. PDT.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments for serious diseases and conditions, including improving function in individuals paralyzed as a result of traumatic spinal cord injury. The Company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the Company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in our filings with the SEC, including our Form 10-K and 10-Q’s and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
|AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas ()|
|Ocera Therapeutics to Present at Piper Jaffrey Healthcare Conference (2013/11/26)|
|Five Prime Therapeutics to Present at Piper Jaffray Healthcare Conference (2013/11/20)|
|Esperion Therapeutics to Present at Credit Suisse Healthcare Conference (2013/11/5)|
|InVivo Therapeutics to Present at 15th Annual Rodman and Renshaw Healthcare Conference (2013/9/5)|
|Stemline Therapeutics to Present at the Aegis Capital Corporation 2013 Healthcare Conference (2013/9/19)|
|Alcobra Ltd. to Present at the Aegis Capital 2013 Annual Healthcare Conference on September 26th in Las Vegas (2013/9/19)|
|Durata Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference (2013/11/15)|
|Hyperion Therapeutics to Present at the Jefferies 2013 London Healthcare Conference ()|
|Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference ()|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.